TransMedics Group, Inc. filings document a Nasdaq-listed medical technology company built around the Organ Care System, National OCS Program and related transplant logistics services for lung, heart and liver transplantation. Its 8-K reports furnish operating results, guidance, tax valuation allowance disclosures and business drivers such as OCS case utilization, logistics revenue and aircraft assets.
Other filings cover material agreements, including headquarters facilities and completed aircraft acquisitions, as well as executive transitions, compensatory arrangements, inducement awards and proxy-governance matters. The company's disclosures also describe its common stock listing, board and shareholder voting matters, executive compensation, clinical program updates and FDA-related device disclosures.
TransMedics Group’s President and CEO Waleed H. Hassanein, through the Waleed H. Hassanein Revocable Trust, reported open‑market purchases of the company’s common stock. On August 6, 2025, the trust bought 8,400 shares at a weighted average price of $118.68.
On August 7, 2025, the trust made additional open‑market purchases of 6,617 shares at a weighted average price of $116.08 and 1,858 shares at a weighted average price of $116.85. After these transactions, the trust indirectly held 486,234 shares, and Hassanein directly held 121,424 shares.
Form 4 summary: Reporting person Edward M. Basile (Director) filed a Form 4 for TransMedics Group, Inc. (TMDX) reporting transactions dated 08/04/2025.
Key reported items
- Non-derivative rows list 4,143 shares associated with a transaction code M and a quoted price of $0.70.
- A contemporaneous non-derivative row lists 4,143 shares with transaction code S and a price of $125.51.
- Post-transaction beneficial ownership figures shown: 7,009 shares and 2,866 shares (as reported).
- Derivative disclosure: a stock option with conversion/exercise price $0.70, underlying 4,143 common shares, exercisable 02/16/2026, and 4,142 derivative securities reported as beneficially owned following the transaction.
- Explanations state the option is fully vested and was adjusted on a 3.5-for-1 basis in connection with a pre-IPO conversion.
Filing: Signed by Attorney-in-Fact Gerardo Hernandez on 08/05/2025.